849767-21-1

基本信息
3-(((叔丁基二甲基甲硅烷基氧基)乙基)-4-氧代哌啶-1-甲酸叔丁酯
3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-4-氧代哌啶-1-羧酸叔丁酯
3-[[(tert-Butyldimethylsilyl)oxy]methyl]-1-Boc-piperidin-4-one
1-BOC-3-[(1,1-DIMETHYLETHYL)DIMETHYLSILYLOXYMETHYL]-PIPERIDIN-4-ONE
3-((tert-butyldimethylsilyloxy)methyl)-4-oxopiperidine-1-carboxylate
1,1-Dimethylethyl 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4-oxo-1-pipe…
tert-Butyl 3-(((tert-butyldiMethylsilyl)oxy)Methyl)-4-oxopiperidine-1-carboxylate
1-Piperidinecarboxylicacid,3-[[[(1,1-diMethylethyl)diMethylsilyl]oxy]Methyl]-4-oxo-,1,1-diMethylethylester
物理化学性质
制备方法
![1-Piperidinecarboxylic acid, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4-hydroxy-, 1,1-dimethylethyl ester](/CAS/20210305/GIF/849767-20-0.gif)
849767-20-0

849767-21-1
将草酰氯(5.71 g,0.0450 mol)溶解于无水二氯甲烷(125 mL)中,并在氮气保护下冷却至-78℃。通过加料漏斗缓慢滴加溶解于无水二氯甲烷(25 mL)中的二甲基亚砜(7.03 g,6.4 mL,0.0900 mol)。反应混合物在-78℃下搅拌15分钟后,通过加料漏斗滴加溶解于无水二氯甲烷(50 mL)中的化合物16(12.40 g,0.0360 mol)。继续在-78℃下搅拌60分钟,随后加入三乙胺(10.92 g,15.0 mL,0.108 mol),反应混合物在-78℃下再搅拌20分钟,然后升温至0℃搅拌30分钟。反应完成后,加入水(200 mL)淬灭反应,分离有机层,水层用二氯甲烷萃取。合并有机相,用无水硫酸镁干燥,过滤并浓缩。通过硅胶柱色谱法(洗脱剂:乙酸乙酯/己烷,1:4)纯化,得到产物17(11.90 g,0.0347 mol,收率97%)为浅黄色油状物。质谱(FAB-MS):m/e 344。
参考文献:
[1] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 5, p. 1375 - 1378
[2] Patent: US2005/182095, 2005, A1. Location in patent: Page/Page column 19
[3] Patent: WO2015/6280, 2015, A1. Location in patent: Paragraph 00192; 00195
[4] Patent: WO2018/2220, 2018, A1. Location in patent: Page/Page column 133
[5] Patent: US2018/72743, 2018, A1. Location in patent: Paragraph 1614-1615